Anti-EGFR Therapy: Mechanism and Advances in Clinical Efficacy in Breast Cancer.
Anti-EGFR Therapy: Mechanism and Advances in Clinical Efficacy in Breast Cancer.
复制标题
DOI：
10.1155/2009/526963
复制
发表时间：
2009
影响因子：
--
通讯作者：
Wu JM
中科院分区：
文献类型：
--
作者：
Flynn JF;Wong C;Wu JM
本文就抗表皮生长因子受体（anti-EGFR）在乳腺癌治疗中的应用作一综述。EGFR是ErbB酪氨酸激酶受体家族的一员，选择EGFR是因为有证据表明其在各种抗EGFR治疗中的作用。因此，我们对EGFR机制和信号传导的理解的增加可能会揭示适合临床干预的新靶点。这一知识库还可能改善现有的医疗方案，并确定新治疗药物设计方面的研究差距。虽然双激酶抑制剂拉帕替尼等药物的批准使用代表了乳腺癌临床管理的重大进展，但必须考虑进行确证性研究，以促进抗EGFR治疗的使用，包括安全性，药代动力学和临床疗效。
This review will focus on recent advances in the application of antiepidermal growth factor receptor (anti-EGFR) for the treatment of breast cancer. The choice of EGFR, a member of the ErbB tyrosine kinase receptor family, stems from evidence pinpointing its role in various anti-EGFR therapies. Therefore, an increase in our understanding of EGFR mechanism and signaling might reveal novel targets amenable to intervention in the clinic. This knowledge base might also improve existing medical treatment options and identify research gaps in the design of new therapeutic agents. While the approved use of drugs like the dual kinase inhibitor Lapatinib represents significant advances in the clinical management of breast cancer, confirmatory studies must be considered to foster the use of anti-EGFR therapies including safety, pharmacokinetics, and clinical efficacy.